These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29446744)

  • 21. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends.
    Checa MA; Prat M; Robles A; Carreras R
    Fertil Steril; 2006 Mar; 85(3):573-7. PubMed ID: 16500321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary.
    Collado B; Carmena MJ; Cortés J; Schally AV; Prieto JC
    Int J Oncol; 2004 Mar; 24(3):725-30. PubMed ID: 14767559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will GnRH antagonists improve prostate cancer treatment?
    Huhtaniemi I; White R; McArdle CA; Persson BE
    Trends Endocrinol Metab; 2009 Jan; 20(1):43-50. PubMed ID: 19008119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix.
    Zijlstra GS; Hinrichs WL; de Boer AH; Frijlink HW
    Eur J Pharm Sci; 2004 Oct; 23(2):139-49. PubMed ID: 15451002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
    Büchter D; Behre HM; Kliesch S; Chirazi A; Nieschlag E; Assmann G; von Eckardstein A
    Exp Clin Endocrinol Diabetes; 1999; 107(8):522-9. PubMed ID: 10612483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats.
    Lizio R; Klenner T; Borchard G; Romeis P; Sarlikiotis AW; Reissmann T; Lehr CM
    Eur J Pharm Sci; 2000 Jan; 9(3):253-8. PubMed ID: 10594381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs.
    Schwahn M; Schupke H; Gasparic A; Krone D; Peter G; Hempel R; Kronbach T; Locher M; Jahn W; Engel J
    Drug Metab Dispos; 2000 Jan; 28(1):10-20. PubMed ID: 10611134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
    Diedrich K; Ludwig M; Felberbaum RE
    Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation.
    Fanchin R; Castelo Branco A; Kadoch IJ; Hosny G; Bagirova M; Frydman R
    Fertil Steril; 2004 Jun; 81(6):1554-9. PubMed ID: 15193476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
    Kovacs M; Schally AV
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study.
    Olivennes F; Fanchin R; Bouchard P; Taïeb J; Selva J; Frydman R
    Hum Reprod; 1995 Jun; 10(6):1382-6. PubMed ID: 7593501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6.
    Hamdine O; Broekmans FJ; Eijkemans MJ; Lambalk CB; Fauser BC; Laven JS; Macklon NS;
    Fertil Steril; 2013 Sep; 100(3):867-74. PubMed ID: 23809501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.